Walgreens Boots Alliance (NASDAQ:WBA) Posts Earnings Results, Beats Expectations By $0.13 EPS

Walgreens Boots Alliance (NASDAQ:WBA) released its earnings results on Friday. The pharmacy operator reported $0.51 EPS for the quarter, beating the consensus estimate of $0.38 by $0.13, RTT News reports. The business had revenue of $39.50 billion during the quarter, compared to analyst estimates of $37.40 billion. Walgreens Boots Alliance had a negative net margin of 5.85% and a positive return on equity of 14.23%. The business’s quarterly revenue was up 7.6% on a year-over-year basis. During the same period in the prior year, the business earned $0.66 earnings per share. Walgreens Boots Alliance updated its FY 2025 guidance to 1.400-1.800 EPS and its FY25 guidance to $1.40-$1.80 EPS.

Walgreens Boots Alliance Price Performance

NASDAQ WBA opened at $11.76 on Friday. The company has a market cap of $10.15 billion, a P/E ratio of -1.17, a P/E/G ratio of 1.36 and a beta of 0.64. Walgreens Boots Alliance has a 1 year low of $8.08 and a 1 year high of $24.93. The company has a current ratio of 0.68, a quick ratio of 0.37 and a debt-to-equity ratio of 0.67. The company has a fifty day simple moving average of $9.26 and a 200 day simple moving average of $9.85.

Walgreens Boots Alliance Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, December 12th. Stockholders of record on Monday, November 18th were paid a $0.25 dividend. This represents a $1.00 dividend on an annualized basis and a dividend yield of 8.50%. The ex-dividend date was Monday, November 18th. Walgreens Boots Alliance’s payout ratio is -9.99%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on WBA shares. Jefferies Financial Group cut their target price on Walgreens Boots Alliance from $19.00 to $9.00 and set a “hold” rating on the stock in a research report on Wednesday, October 23rd. Barclays raised their target price on shares of Walgreens Boots Alliance from $7.00 to $8.00 and gave the stock an “underweight” rating in a report on Wednesday, October 16th. Truist Financial cut their price target on shares of Walgreens Boots Alliance from $13.00 to $10.00 and set a “hold” rating on the stock in a report on Monday, October 7th. UBS Group raised their price objective on shares of Walgreens Boots Alliance from $9.00 to $10.00 and gave the stock a “neutral” rating in a research note on Thursday, October 17th. Finally, Royal Bank of Canada reduced their target price on Walgreens Boots Alliance from $13.00 to $9.00 and set a “sector perform” rating for the company in a report on Wednesday, December 4th. Four analysts have rated the stock with a sell rating, nine have issued a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $12.58.

Walgreens Boots Alliance Company Profile

Walgreens Boots Alliance, Inc operates as a healthcare, pharmacy, and retail company in the United States, the United Kingdom, Germany, and internationally. It operates through three segments: U.S. Retail Pharmacy, International, and U.S. Healthcare. The U.S. Retail Pharmacy segment engages in operation of the retail drugstores, health and wellness services, specialty, and home delivery pharmacy services, which offers health and wellness, beauty, personal care and consumables, and general merchandise.